Compare AstraZeneca plc (AZN) vs Qurate Retail Inc Series A (QVCAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Qurate Retail Inc Series A — how do they compare? AstraZeneca plc trades at $168.35 (market cap $253.13B), while Qurate Retail Inc Series A trades at $0.1 (market cap $1.05M). The key difference: AstraZeneca plc is far larger — about 241076.2× Qurate Retail Inc Series A's market cap, and AstraZeneca plc pays a 1.92% dividend while Qurate Retail Inc Series A pays none. Which is the better fit depends on your goals.
| AZN | QVCAQ | |
|---|---|---|
Market Cap | $253.13B | $1.05M |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $15.03 |
52-Week Low | $137.44 | $0.07 |
Enterprise Value | $279.37B | $4.74B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
QVCAQ trades at $0.082, down 9.99% today, with a bearish technical outlook showing 13 sell signals versus 3 buy signals. Fundamentally, the company reported a net loss of $2.44 billion in 2025 on $9.23 billion revenue, with negative shareholder equity of $971 million and concerning debt-to-asset ratio of 77.57%. Recent earnings show volatility with one beat and three misses in the last four quarters.
The stock faces significant headwinds from persistent losses, negative equity, and high leverage. While QVC's recent brand celebration shows ongoing operations, the financial deterioration and bearish technical indicators suggest caution. Recovery depends on sustainable profitability improvement and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →
